Stada Arzneimittel AG is in a better position for an initial public offering this fall, the German drugmaker’s chief executive said, boosting prospects for Europe’s market after delaying plans earlier this year. https://t.co/3IcUI8GUXL ...

Novo shares advanced after the drugmaker’s blockbuster weight-loss drug Wegovy received US approval to treat a serious form of liver disease https://t.co/Fi1V1nX2Rn ...

Leadership Change - Bristol-Myers CEO is stepping down after six years [1] - The move is considered a surprise as the company seeks its next successful drug [1] Industry Focus - The pharmaceutical company is in a race to discover its next blockbuster drug [1]

Market Assessment - HC Wainwright analysts suggest Sarepta shares have zero value [1] - This assessment follows regulatory interactions that could lead to market withdrawal of Elevidys treatment [1] Regulatory Impact - US regulators' actions could result in the withdrawal of Sarepta's Elevidys treatment from the market [1]